# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...
Cantor Fitzgerald analyst Sarah James reiterates Cigna Group (NYSE:CI) with a Overweight and maintains $384 price target.